Search results
Showing 856 to 870 of 1490 results for patients and public
Awaiting development Reference number: GID-TA11695 Expected publication date: TBC
Awaiting development Reference number: GID-TA11583 Expected publication date: TBC
Awaiting development Reference number: GID-TA11658 Expected publication date: TBC
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]
In development Reference number: GID-TA11886 Expected publication date: TBC
In development Reference number: GID-TA11809 Expected publication date: TBC
In development Reference number: GID-TA11052 Expected publication date: TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
In development Reference number: GID-TA11782 Expected publication date: TBC
In development Reference number: GID-TA11820 Expected publication date: TBC
This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented
This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.
View quality statements for QS101Show all sections
Sections for QS101
- Quality statements
- Quality statement 1: Lead commissioner
- Quality statement 2: Annual health check
- Quality statement 3: Initial assessment of behaviour that challenges
- Quality statement 4: Named lead practitioner
- Quality statement 5: Involving families and carers
- Quality statement 6: Parent-training programmes
- Quality statement 7: Personalised daily activities
In development Reference number: GID-IPG10392 Expected publication date: TBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]
Awaiting development Reference number: GID-TA11688 Expected publication date: TBC
Awaiting development Reference number: GID-TA11660 Expected publication date: TBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]
In development Reference number: GID-TA11780 Expected publication date: TBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]
In development Reference number: GID-TA11071 Expected publication date: TBC